Brent Fraser is CADTH Vice-President, Pharmaceutical Reviews, with responsibility for the CADTH drug products and services including the CADTH Common Drug Review (CDR), the pan-Canadian Oncology Drug Review (pCODR).
Brent is dedicated to building a team-based, client-oriented culture that values leadership, excellence, collaboration, and responsiveness. He champions customer service, business discipline, and ongoing process improvement, and he challenges his team to deliver high-quality, relevant, and timely assessments of drugs using the best available science, tools, and methodologies.
Brent is known for his strength as a thoughtful, listening, and collaborative leader who is adept at translating evidence into recommendations and actions. He combines a pharmacist’s appreciation for the clinical and human implications of his work with almost two decades of strategic experience within the largest public drug plan in the country.
Prior to joining CADTH in 2015, Brent held a variety of positions within the Ontario Public Drug Programs, where he was a key leader in the development of a pan-Canadian approach to pharmaceutical negotiations. Prior to that he was a pharmacist at the Hospital for Sick Children in Toronto.
Day 1: Oct 6, 2020
Analyse the Impact of Changes to CADTH’s New Review Process
A number of changes have recently been made to the CADTH drug review process. Gain critical insight that will help you understand and analyse the impact of these changes for your company. Source intelligence to:
- Better understand the information requirements for drug submissions to CADTH;
- Adopt best practices to better manage your product submissions under the revised process;
- Adopt an efficient approach to navigating through this new review process
Position your product for successful navigation through the revised review process
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020